MedTrace Logo

SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

NCT02945813 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2022-04-14

No results posted yet for this study

Summary

The main objective of the trial is to explore the efficacy of salvage radiotherapy (SRT) plus metformin compared to SRT in the endpoint of time to progression after prostatectomy failure.

Conditions

Interventions

DRUG

Metformin

850mg PO BID; 48 weeks

RADIATION

Salvage Radiotherapy SRT

SRT 35 x 2Gy; 7 weeks

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Daniel M. Aebersold, Prof · Bern University Hospital - Radiation Oncology

  • Alan Dal Pra, MD · Miller School of Medicine, University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • France
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945813 on ClinicalTrials.gov